The effects of valsartan treatment on visfatin levels and lipid profiles in newly diagnosed hypertensives

Aim: In this study, the curative effect of valsartan on hypertension based on its effect on visfatin levels and lipid profiles was investigated.Materials and methods: Forty patients aged 38–60 with hypertension were included in the study. In order to determine initial visfatin levels and lipid profiles, blood samples were taken from the patients and all were started on 80-mg valsartan tablets. All patients were monitored for 12 weeks.Results: By using multivariate regression analysis, it was determined that visfatin levels affected systolic blood pressure (SBP) (P = 0.012, beta; –0.43, 95% CI: –0.092 to –0.012). After the patients received the valsartan treatment for 12 weeks, a significant increase in visfatin levels was observed (pre- and posttreatment, respectively: 0.42 ± 0.22 ng/mL and 0.71 ± 0.36 ng/mL, P 0.001). When the lipid profile changes of patients were examined, only low-density lipoprotein (LDL) levels showed a statistically significant change (pre- and posttreatment, respectively: 150.32 ± 13.22 mg/dL and 143.82 ± 7.53 mg/dL, P = 0.008).Conclusion: In this study, it was found that visfatin levels affected SBP in newly diagnosed hypertensive patients and valsartan treatment increased visfatin levels. In addition, the use of valsartan reduced LDL levels.